Clinical trials: Type 2 Diabetes Patients
Diabetes Mellitus, Type 2
Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
MK-8835-016 (B1521006) is designed to evaluate the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729) in participants with Type 2 diabetes mellitus.
- Trial name
- NCT01059825
- Testing
- Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg
- Volunteers
- 375 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
This study is conducted to determine the most appropriate therapeutic doses of BI 10773 in Japanese patients with T2DM at first treatment period.
- Trial name
- NCT01193218
- Testing
- BI 10773
- Where
- 32 sites in Japan
- Volunteers
- 547 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
The Effect of Biscuit Containing Kothala Himbutu on Blood Glucose in Patients With Diabetes. A Randomized Control Study
The investigators intend to conduct a triple blind randomized clinical trial to investigate the effect of a biscuit containing herbal extract, available in the market on the fasting blood sugar control in patients with diabetes…
- Trial name
- NCT02290925
- Testing
- Kothala Himbutu Biscuit
- Where
- Sri Lanka
- Volunteers
- 133 people
- Sponsor
- Rajarata University, Sri Lanka
Diabetes Mellitus, Type 2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM…
- Trial name
- NCT00749190
- Testing
- BI 10773, sitagliptin
- Where
- 116 sites in United States, Argentina and 14 more
- Volunteers
- 495 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Local Anesthesia
Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2
The purpose of this study is to determine whether 2% lidocaine (L) + clonidine (C) (15 mcg/ml) as a vasoconstrictor achieves efficient (equal or better parameters of intraoral local anesthesia in comparison to 2% lidocaine +…
- Trial name
- LCIOADMT2 (NCT02371759)
- Testing
- L+C maxillary anesthesia, L+C mandibular anesthesia, L+E maxillary anesthesia
- Where
- Serbia
- Volunteers
- 256 people
- Sponsor
- University of Belgrade
Type 2 Diabetes
A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes.
- Trial name
- AWARD-PEDS (NCT02963766)
- Testing
- Dulaglutide
- Where
- 61 sites in United States, Brazil and 9 more
- Volunteers
- 154 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study for Patients With Type 2 Diabetes
Comparison of fasting blood glucose levels in patients with Type 2 diabetes after 12 weeks of treatment with a new basal insulin analog or with insulin glargine.
- Trial name
- NCT01027871
- Testing
- LY2605541, insulin glargine
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 289 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes
This study evaluates a mobile phone-delivered intervention, called REACH (Rapid Education/Encouragement And Communications for Health), in supporting adults with type 2 diabetes in their self-management relative to a control…
- Trial name
- NCT02409329
- Testing
- REACH, Helpline and A1c results, REACH + FAMS
- Where
- United States
- Volunteers
- 512 people
- Sponsor
- Vanderbilt University Medical Center
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, used in a 2-step dose titration regimen in monotherapy, over a period of 12 weeks of treatment.
- Trial name
- GETGOAL-MONO (NCT00688701)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector
- Where
- 12 sites in United States, Belgium and 10 more
- Volunteers
- 361 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Comprehensive Add on Study in Japan
The objective of the current study is to investigate the safety and efficacy of linagliptin (5mg / once daily) given for 52 weeks as add-on therapy to patients with type 2 diabetes mellitus and insufficient glycaemic control…
- Trial name
- NCT01204294
- Testing
- Linagliptin, Metformin
- Where
- 43 sites in Japan
- Volunteers
- 574 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus
The purpose of this study is: To assess the efficacy of Nasulin vs. placebo as indicated by time spent in euglycemia, assessed by continuous glucose monitoring data and serum fructosamine levels in patient volunteers with Type 2…
- Trial name
- CPEX-011 (NCT00850096)
- Testing
- Nasulin
- Where
- 21 sites in United States
- Volunteers
- 94 people
- Sponsor
- CPEX Pharmaceuticals Inc.
Type 2 Diabetes Mellitus
A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes
The purposes of this study is to evaluate the efficacy and safety of SYR-472 when administered at a dose of 100 mg once weekly as an add-on to insulin therapy compared with placebo in patients with type 2 diabetes mellitus and…
- Trial name
- NCT02324569
- Testing
- SYR-472
- Where
- 65 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Takeda
Type 2 Diabetes
The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Background: Dedicated renal hemodynamic and renal function studies are lacking for DPP-4 inhibitors in patients with Type 2 diabetes; accordingly little is known regarding the mechanisms mediating the renal effects of DPP-4…
- Trial name
- INDORSE (NCT02406443)
- Testing
- Sitaglitpin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Type 2 Diabetes Mellitus
A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)
A multiple dose study to assess the safety and pharmacokinetics of an investigational drug in patients with type 2 diabetes. The primary hypotheses of the study are that multiple daily MK-0941 in subjects with T2DM with or…
- Trial name
- NCT00511667
- Testing
- MK0941
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Cardiovascular Disease
Cardiovascular Inflammation Reduction Trial
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic…
- Trial name
- CIRT (NCT01594333)
- Testing
- Methotrexate
- Where
- 470 sites in United States, Canada and 1 more
- Volunteers
- 4,786 people
- Sponsor
- Brigham and Women's Hospital
Obesity, Type2 Diabetes
Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes
The objective of the analysis was to evaluate the relationship between bariatric surgery and cardiovascular outcomes in obese patients with type 2 diabetes.
- Conditions
- Obesity, Type2 Diabetes, Bariatric Surgery Candidate
- Trial name
- NCT03955952
- Testing
- Bariatric Surgery
- Where
- United States
- Volunteers
- 91,700 people
- Sponsor
- The Cleveland Clinic
Diabetes Mellitus, Type 2
A Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is: To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. To compare the rate of night time low blood sugar episodes on LY2605541 with insulin glargine during 52…
- Trial name
- IMAGINE 2 (NCT01435616)
- Testing
- Glargine, LY2605541
- Where
- 167 sites in United States, Argentina and 21 more
- Volunteers
- 1,538 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.
- Trial name
- NCT00660907
- Testing
- dapagliflozin, glipizide, metformin hydrochloride
- Where
- 76 sites in Argentina, France and 8 more
- Volunteers
- 1,217 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)
A study to compare safety and efficacy of sitagliptin and placebo therapy when added to stable sulfonylurea alone or in combination with metformin in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01590771
- Testing
- Sitagliptin, Gliclazide, Glimepiride
- Volunteers
- 498 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2, Congestive Heart Failure
Improving Patient Prioritization During Hospital-homecare Transition
This research work is focused on building and evaluating one of the first evidence-based clinical decision support tools for homecare in the United States.
- Conditions
- Diabetes Mellitus, Type 2, Congestive Heart Failure, Obstructive Pulmonary Disease, Dyspnea
- Trial name
- PREVENT (NCT04136951)
- Testing
- PREVENT clinical decision support
- Where
- 2 sites in United States
- Volunteers
- 1,915 people
- Sponsor
- Columbia University